Sulofenur
Sulofenur (Diarylsulfonylurea; LY186641) is an orally active anti-tumor agent. Sulofenur induces gene expression through calcium ion-dependent pathways and some protein kinase-independent pathways, and its effect is particularly enhanced in H-ras mutant cells. Sulofenur exhibits significant activity in mouse solid tumor models and human tumor xenograft models[1][2][3].
Product Specifications
CAS Number
110311-27-8
Product Name Alternative
Diarylsulfonylurea; LY186641
UNSPSC
12352005
Target
Calcium Channel
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=S(C1=CC2=C(CCC2)C=C1)(NC(NC3=CC=C(Cl)C=C3)=O)=O
Molecular Formula
C16H15ClN2O3S
Molecular Weight
350.82
References & Citations
[1]Gu H, et al. H-ras transfection of the rat kidney cell line NRK-52E results in increased induction of c-fos, c-jun and hsp70 following sulofenur treatment. Cancer Lett. 1996 Sep 10;106 (2) :199-205.|[2]Brown TD, et al. Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule. Anticancer Drugs. 1994 Apr;5 (2) :151-9.|[3]Ehlhardt WJ, et al. Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs. J Pharm Sci. 1993 Jul;82 (7) :683-8.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog